背景:肺癌是全球癌症相关死亡率的最常见原因之一。通过支持肿瘤生长,血小板已成为癌症发展和进展的关键参与者,和传播。在本系统综述中,我们分析了癌细胞和血小板之间的RNA转移,并探讨了不同血小板RNA谱在诊断中的潜在作用,亚型,肺癌的疾病进展和治疗监测。
方法:该研究遵循了系统评价和Meta分析指南的首选报告项目和Cochrane系统评价和Meta分析手册,其中包括七项关于肺癌患者的研究,有肿瘤检测血小板的数据,和对照组。测量的结果是基于敏感性,特异性,ROC。pubmed,Scopus,在2023年10月之前,使用特定的搜索词搜索了Cochrane中央对照试验登记处和ScienceDirect数据库。QUADAS-2工具用于评估质量,偏差风险和适用性问题。
结果:分析显示不同血小板mRNA的AUC>70%,敏感性和特异性超过60%。ITGA2B的AUC和灵敏度最高(AUC0.922;灵敏度92.8%)。lncRNAGTF2H2-1是最特异的血小板RNA。在QUADAS-2工具上,3/7文章在参考标准中不清楚,患者流量计时,1/7在这两个方面都有较高的偏倚。为了适用性,1/7的研究在参考标准中不清楚,和2/7指数测试。
结论:TEPRNA可以帮助肺癌的早期诊断,并在其早期检测中得到证实。TEPRNA还可以监测疾病进展和治疗反应。
BACKGROUND: Lung cancer is one of the commonest cause of cancer associated mortality worldwide. Platelets have emerged as key players in cancer development and progression by supporting tumor growth, and dissemination. In the present systematic
review, we analyzed RNA transfer between cancer cells and platelets and explored potential role of different platelet RNA profiles as onco-signature in diagnosis, subtyping, disease progression and treatment monitoring in carcinoma lung carcinoma.
METHODS: The study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and Cochrane Manual of Systematic Reviews and Meta-analysis that included seven studies on patients with lung cancer, with data on tumor-educated platelets, and control group. The outcome measured was based on sensitivity, specificity, and ROC. PUBMED, SCOPUS, Central Cochrane Registry of Controlled Trials and Science Direct databases were searched using specific search terms until October 2023. QUADAS - 2 tool was used to assess quality, risk of bias and applicability concerns.
RESULTS: The analysis revealed AUC > 70% for different platelet mRNAs, with sensitivity and specificity of more than 60 %. AUC and sensitivity were highest for ITGA2B (AUC 0.922; sensitivity 92.8%). lncRNA GTF2H2-1 was the most specific platelet RNA. On QUADAS-2 tool, 3/7 articles were unclear in reference standards, patient flow timing, and 1/7 had high bias in both aspects. For applicability, 1/7 studies were unclear in reference standards, and 2/7 in index tests.
CONCLUSIONS: TEP RNA can aid in early diagnosis of lung cancer and of proven utility in its early-stage detection. TEP RNA can also monitor disease progression and treatment response.